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ABSTRACT
CLL remains an incurable disease in spite of the many new compounds being 
tested. Arsenic trioxide (ATO) induces apoptosis in all CLL cell types and could 
constitute an efficient therapy. To further explore this, we have studied the gene 
expression profile induced by ATO in CLL cells. ATO modulated many genes, largely 
involved in oxidative stress, being HMOX1 the most upregulated gene, also induced at 
the protein level. ATO also increased MMP-9, as we previously observed, both at the 
mRNA and protein level. Using specific inhibitors, qPCR analyses, and gene silencing 
approaches we demonstrate that upregulation of MMP-9 by ATO involved activation of 
the p38 MAPK/AP-1 signaling pathway. Moreover, gene silencing HMOX1 or inhibiting 
HMOX1 activity enhanced p38 MAPK phosphorylation and c-jun expression/activation, 
resulting in transcriptional upregulation of MMP-9. Overexpression of HMOX1 or 
enhancement of its activity, had the opposite effect. Cell viability analyses upon 
modulation of HMOX1 expression or activity demonstrated that HMOX1 had a pro-
apoptotic role and enhanced the cytotoxic effect of ATO in CLL cells. We have therefore 
identified a new mechanism in which HMOX1 plays a central role in the response of 
CLL cells to ATO and in the regulation of the anti-apoptotic protein MMP-9. Thus, 
HMOX1 arises as a new therapeutic target in CLL and the combination of HMOX1 
modulators with ATO may constitute an efficient therapeutic strategy in CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
characterized by the accumulation of malignant CD5+ B 
lymphocytes in the peripheral blood and lymphoid tissues 
[1, 2]. CLL is very heterogeneous and patients carrying 
certain bad prognostic markers (del17p13, unmutated 
IgHv) do not respond well to conventional therapies [1-3]. 
The recent development of more specific agents, such as 
ibrutinib and idelalisib, has greatly improved the response 
of most CLL patients [4, 5]. However, the long-term 
efficacy of these treatments, particularly in refractory CLL 
cases, is not known and CLL remains an incurable disease. 
Therefore, it is still crucial to continue searching for new 
compounds for CLL treatment, especially in the advanced 
setting.
Arsenic trioxide (ATO) is an efficient therapy 
in acute promyelocytic leukemia [6] and has shown 
promising results in other malignancies [7]. We and others 
have shown that ATO induces apoptosis in all CLL cases, 
including those with unfavorable prognosis [8-10]. As part 
of the apoptotic mechanism, ATO induces JNK activation, 
reactive oxygen species (ROS) generation and PI3K/Akt/
NF-κB downregulation in CLL cells [10]. Additionally, 
we have shown that ATO upregulates membrane-bound 
matrix metalloproteinase-9 (MMP-9), and that MMP-9 
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protects CLL cells against the cytotoxic effect of ATO, 
contributing to the anti-apoptotic effect of stroma [11, 12]. 
In spite of these advances, ATO functions through multiple 
mechanisms and the complete response elicited by this 
agent in CLL cells has not been established.
It is well known that the pro-apoptotic effects of 
ATO are mainly via generation of ROS and oxidative stress 
[13]. Heme oxygenase-1 (HMOX1, HO-1) is the main 
antioxidant enzymatic system in the cell, with crucial roles 
in the removal of intracellular ROS, and in the regulation 
of several biological processes, including cell survival, 
proliferation and inflammation [14-16]. ATO enhances 
HMOX1 production in many cell systems, mostly via ROS-
stimulated signaling pathways [14, 16-18]. Many evidences 
in the literature support an anti-apoptotic and protective role 
for HMOX1 in a variety of injury models [19-21]. However, 
it has also been described that these protective properties 
are restricted to a rather narrow threshold of overexpression 
[22], and that HMOX1 is neither exclusively cytoprotective 
nor exclusively cytotoxic [15].
CLL cells display intrinsic high levels of ROS/
oxidative stress and upregulated HMOX1 expression, 
compared to normal B cells and these characteristics 
could constitute therapeutic targets [23, 24]. To help 
develop these strategies, a better knowledge of the role 
of HMOX1 in CLL as well as of the molecular pathways 
elicited by clinically relevant concentrations of ATO 
is needed. To address these issues, in the present report 
we have performed gene expression and functional 
analyses on CLL cells treated with ATO. We show that, by 
modulating the p38 MAPK signaling pathway, HMOX1 
downregulates MMP-9 expression and contributes to 
ATO-induced cytotoxicity.
RESULTS
Gene expression profile triggered by ATO in 
CLL cells
To gain further insight into the mechanisms 
underlying the induction of CLL cell apoptosis by ATO 
we analyzed the gene expression profile upon treatment 
with this agent. The MEC-1 cell line (CLL-derived) 
was used for this purpose. To first determine the optimal 
conditions for the gene expression study, MEC-1 cells 
were incubated with several concentrations of ATO and 
their viability measured by flow cytometry after 24 and 
48 h. As shown in Figure 1 and in agreement with our 
previous results [11], ATO decreased the viability of 
MEC-1 cells in a dose-dependent manner, after 24 (Figure 
1A) or 48 h (Figure 1B). After 24 h of treatment with 5 
μM ATO, approximately 50% of MEC-1 cells remained 
viable and these conditions were chosen for subsequent 
gene expression analyses. A similar dose-response effect 
was also observed for primary CLL cells, albeit ATO was 
more effective in this case and was used up to 3 μM to 
avoid excessive cell death (Figure 1C, 1D).
Initial data from gene microarray analyses of MEC-
1 cells rendered a total of 738 differentially expressed 
genes (384 downregulated, 354 upregulated) between 
control and ATO-treated cells (GEO ID: GSE78207; 
website: http://www.ncbi.nlm.nih.gov/geo/). From these, 
we selected genes whose expression change was ≥ 
2-fold, resulting in 148 genes (62 downregulated and 86 
upregulated). Upon a second filtering process (elimination 
of genes encoding uncharacterized proteins or transcripts 
with little or no evidence at the protein level, pseudogenes 
and genes encoding Y RNA), a total of 131 differentially 
expressed genes (52 downregulated, 79 upregulated) were 
obtained (Figure 2A and Supplementary Table S1).
To validate the microarray results we selected several 
upregulated or downregulated genes and analyzed them by 
qPCR in MEC-1 cells. The four selected upregulated genes 
(CTSB, SQSTM1, MAP1LC3B2, CLU) were related to 
processes involving cell death (Supplementay Tables S1 and 
S2). For downregulated genes we randomly selected four 
genes among the most downregulated by ATO (CXCL10, 
NUDT7, CBR4, SPINK2) (Supplementary Tables S1 and 
S2). qPCR analyses confirmed the up- or downregulation, 
respectively, of the selected genes, in response to the two 
concentrations of ATO used, 3 and 5 μM (Figure 2B). 
Additionally, and to confirm that the results obtained in 
the microarray analysis reflected a general response of 
CLL cells to ATO, we validated the same selected genes 
on the EHEB cell line, also of CLL origin [25]. In initial 
analyses, ATO decreased the viability of EHEB cells in a 
dose-dependent manner, yielding 51.8% and 27.6% viable 
cells after 24 h treatment with 3 and 5 μM ATO, respectively 
(Supplementary Figure S1). Analyses by qPCR confirmed 
the upregulation of CTSB, SQSTM1, MAP1LC3B2, and 
CLU, and the down-regulation of CXCL10, NUDT7, and 
CBR4 genes on EHEB cells treated with ATO (Figure 
2C), confirming the results obtained for MEC-1 cells. The 
SPINK2 gene was not detected on EHEB cells.
To further validate the results with the cell lines 
we performed similar qPCR analyses using primary 
CLL cells from patients, treated or not with 2 or 3 μM 
ATO for 24 h. Figure 2D shows that the selected genes 
were also differentially regulated in primary CLL cells in 
response to ATO with respect to control cells. Altogether, 
and in spite of the not surprising fold-change differences 
in gene regulation among different cell types, the qPCR 
results confirmed the data of the microarray analyses and 
established that the observed gene expression profile was 
a general response of CLL cells.
Functional classification of the differentially 
regulated genes by ATO
Having validated the microarray data we carried 
out functional analyses of the 131 genes displayed in 
Figure 2A and Supplementary Table S1, using the DAVID 
database and the biological process (BP_FAT) category 
of Gene Ontology. Upon discarding non-significantly 
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enriched processes, these analyses revealed that ATO 
downregulated genes mainly involved in lipid metabolism, 
immune response and cell adhesion (Figure 2E). The 
significantly upregulated genes had roles in the response 
to oxidative stress, unfolded proteins, hypoxia, organic 
and toxic substances, and regulation of apoptosis, among 
others (Figure 2E). The specific genes included in these 
biological processes and their respective expression values 
(fold-change) are listed in Supplementary Table S2.
Because the main effect of ATO on CLL cells is the 
induction of apoptosis (Figure 1A, 1B and refs [8-10]) we 
focused on the 9 differentially upregulated genes involved 
in the regulation of this process (Supplementary Table 
S2). The expression levels of these genes are graphically 
represented in Figure 3A. The most upregulated gene by 
ATO was HMOX1 (35-fold change), in agreement with 
the strong induction of ROS and oxidative stress caused 
by ATO in CLL and other cell types [10, 13, 26]. Another 
gene upregulated in this analysis was MMP9, confirming 
our previous report and the role of MMP-9 in the apoptotic 
response of CLL cells to ATO [11]. Therefore, we focused 
subsequent studies on HMOX1 (the most upregulated 
gene) and on MMP-9 (with known functions in CLL).
We first validated the above results at the gene 
and protein level. qPCR analyses clearly demonstrated 
that HMOX1 and MMP9 expression was significantly 
increased by treatment of MEC-1 cells with either 3 or 
5 μM ATO (Figure 3B). Moreover, HMOX1 and MMP9 
Figure 1: ATO efficiently induces apoptosis of MEC-1 and primary CLL cells. 1.5 x 105 MEC-1 cells in IMDM/0.1%FBS A, 
B. or 2 x 105 CLL cells in RPMI/0.1%FBS C, D. were cultured with or without the indicated concentrations of ATO for 24 h (A, C) or 48 h 
(B, D). Cell viability was determined by flow cytometry, using FITC-Annexin V and PI. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Figure 2: Gene expression profile triggered by ATO in CLL cells. A. Heat map representing color-coded expression levels of 
131 differently expressed genes (up- or down-regulated ≥ 2-fold and encoding characterized proteins) in ATO-treated vs untreated cells. 
Non-supervised hierarchical clustering of genes and samples is shown. B-D. qPCR validation of selected genes in MEC-1 (B), EHEB (C) 
and primary CLL (D) cells treated or not with ATO for 24 h. TBP expression was used as an internal control and normalized average values 
are shown. White columns, control; grey columns, 3 μM (MEC-1, EHEB) or 2 μM (CLL) ATO; black columns, 5 μM (MEC-1, EHEB) or 3 
μM (CLL) ATO. All data shown are statistically significant (p-value ≤ 0.05). E. Functional annotation of the 131 genes shown in (A) using 
the Biological Process (BP)_FAT category of Gene Ontology and the DAVID database. p-values associated to each biological process are 
shown.
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Figure 3: ATO induces HMOX1 and MMP-9 expression in CLL cells. A. Bar graph representing the expression levels of the 
9 differentially expressed genes involved in the regulation of apoptosis. B-D. 3-5 x 106 MEC-1 cells in IMDM/0.1% FBS (B), 3-5 x 106 
EHEB cells in RPMI/0.1%FBS (C), or 10-15 x 106 primary CLL cells in RPMI/0.1%FBS (D) were treated with the indicated concentrations 
of ATO for 24 h, and MMP9 and HMOX1 mRNA expression was analyzed by qPCR using TBP as internal control. Normalized average 
values are shown. E-F. 3-5 x 106 MEC-1 (E) or EHEB (F) cells were treated or not with 5 μM ATO for the indicated times and analyzed by 
Western blotting (cell lysates) and gelatin zymography (concentrated conditioned media). FC, fold change; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 
0.001, compared to their corresponding controls at each time point.
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were also significantly upregulated upon incubation 
of EHEB cells with 3 or 5 μM ATO (Figure 3C) and of 
primary CLL cells with 2 or 3 μM ATO (Figure 3D), thus 
confirming the results obtained on MEC-1 cells.
To determine whether ATO also regulated HMOX1 
and MMP-9 proteins, MEC-1 cells were treated with 5 
μM ATO for various times and cell lysates analyzed by 
Western blotting. Figure 3E shows that the levels of 
HMOX1 were very low in control cells, in agreement 
with its inducible character, but significantly increased 
after 2 h of exposure to ATO, being even higher after 
24 h of treatment. Gelatin zymography analysis of the 
concentrated conditioned medium of the same cells 
indicated that MMP-9 was also significantly induced after 
24 h of ATO treatment (Figure 3E). Likewise, treatment of 
EHEB cells with ATO clearly increased HMOX1 after 2, 
6, and 24 h (Figure 3F). The amount of MMP-9 secreted 
into the medium, measured by gelatin zymography, was 
also increased after 24 h of cell exposure to ATO (Figure 
3F), confirming that EHEB and MEC-1 cells behaved 
similarly.
ATO regulates MMP-9 expression in CLL cells 
via the p38 MAPK/c-jun signaling pathway
To study the mechanism involved in the regulation 
of MMP-9 by ATO we first analyzed the possible 
activation of relevant kinases. Because we have shown 
that ATO inhibits Akt phosphorylation and activates 
JNK [10], we focused the analysis on members of the 
MAPK family. ATO significantly decreased ERK1/2 
phosphorylation after 6 h of treatment compared to control 
values. This was not due to apoptosis, since at this time 
apoptosis was <1%, determined by FITC-Annexin V/
PI and flow cytometry (not shown). Phospho-ERK1/2 
remained low after 24 h of exposure to ATO (Figure 4A, 
4B). Because of these results, ERK1/2 was disregarded 
as a possible candidate and was not further studied. As 
previously observed in primary CLL cells [10], ATO 
increased JNK phosphorylation in MEC-1 cells after 
2 and 6 h of treatment, then declining (Figure 4A, 4B). 
p38 MAPK was also clearly activated by ATO after 2 h 
and remained significantly phosphorylated after 24 h of 
treatment (Figure 4A, 4B).
To then establish whether JNK and/or p38 MAPK 
regulated MMP-9 expression, we inhibited these 
kinases and measured MMP9 mRNA by qPCR. Figure 
4C shows that, in the presence of ATO, the p38 MAPK 
inhibitor SB203580 significantly reduced (3.8-fold) 
MMP9 mRNA levels after 6 h, while the JNK inhibitor 
SP600125 did not. The combination of both inhibitors 
did not significantly increase the effect of SB203580, 
which was still significant after 24 h of exposure to ATO 
(Figure 4C). The basal expression of MMP9 mRNA in 
the absence of ATO, albeit low, was also significantly 
reduced by the p38 MAPK inhibitor, both after 6 and 24 
h (Figure 4C). Additionally, gelatin zymography analyses 
demonstrated that SB203580, but not SP600125, also 
significantly diminished the levels of MMP-9 secreted 
into the conditioned medium after 24 h of cell treatment 
with ATO (Figure 4D). In the absence of this agent, the 
expression of MMP-9 was very low and differences could 
not be observed (Figure 4D).
We next analyzed whether the transcription 
complex AP-1, a downstream effector of p38 MAPK 
and with several binding sites in the MMP-9 promoter 
[27, 28], was responsible for the upregulation of MMP-
9 by ATO. To this end, we first studied the effect of the 
specific AP-1 inhibitor SR11302 on MMP9 mRNA and 
protein expression. qPCR analyses showed that SR11302 
significantly reduced MMP9 expression in a dose-
dependent manner, after 6 h of treatment with ATO, and 
the effect persisted after 24 h (Figure 5A). At the protein 
level, the AP-1 inhibitor also significantly inhibited 
secreted MMP-9 in a dose-dependent manner, measured 
by gelatin zymography after 24 h of ATO exposure 
(Figure 5B).
To confirm the major role of AP-1 in MMP-9 
regulation we measured by qPCR whether the expression 
of c-jun and c-fos, the main components of the AP-1 
complex, was modulated by ATO. JUN mRNA was 
significantly upregulated after 2 h of exposure to 5 μM 
ATO, with maximum levels after 6 h and still significantly 
higher than controls after 24 h (Figure 5C). ATO did 
not increase FOS mRNA after 2 h of treatment, but at 
longer times, c-fos values remained significantly higher 
in ATO-treated cells than in control cells (Figure 5D). In 
parallel analyses, we measured whether ATO increased 
the expression of NF-κB, another transcription factor 
activated by p38 MAPK and involved in the regulation of 
MMP-9 [27, 28]. qPCR analyses demonstrated that ATO 
did not upregulate NFKB1 mRNA expression at any of the 
times studied (Figure 5E), in agreement with the reported 
inactivation of NF-κB upon ATO treatment of primary 
CLL cells [10].
We next studied whether ATO modulated c-jun and 
c-fos at the protein level. MEC-1 cells were treated or 
not with 5 μM ATO for the same times as above, lysed 
and analyzed by Western blotting. As shown in Figure 
5F for a representative experiment and quantitated for 
the three experiments performed, c-jun phosphorylation 
significantly increased after 2 and 6 h of treatment with 
ATO (2.2 and 2.87 fold, respectively), compared to control 
cells. The expression of total c-jun was also significantly 
increased in response to ATO, remaining significantly 
elevated after 24 h of treatment (Figure 5F). These results 
indicated that the observed modulation of c-jun correlated 
well with the activation of p38 MAPK shown in Figure 
4A, 4B. The expression of c-fos protein, however, was not 
modulated by ATO at the times studied (Figure 5F). To 
then determine whether the NF-κB protein was regulated 
by ATO we measured the phosphorylation and expression 
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of the NF-κB-associated protein IκB, a reporter of NF-
κB activation [29]. Figure 5G shows that ATO did not 
significantly modify either phosphorylated or total IκB, 
in agreement with the results shown in Figure 5E and 
suggesting a null or very low contribution of NF-κB to the 
regulation of MMP-9 by ATO.
To further establish the involvement of c-jun in 
MMP-9 upregulation in response to ATO, we transfected 
MEC-1 cells with two c-jun-specific siRNAs or with 
a control siRNA. This procedure reduced JUN mRNA 
expression 2- and 1.25-fold, respectively, for siJun1 and 
siJun2, determined by qPCR (Figure 6A). Western blotting 
analyses also confirmed the reduction of phospho-c-jun 
protein on cells transfected with siJun1 (1.4-fold) and 
siJun2 (1.25-fold) (Figure 6B). Subsequent qPCR analyses 
of c-jun silenced cells treated with ATO demonstrated a 
reduced expression of MMP9 mRNA by 1.3-fold (siRNA1) 
and 1.25-fold (siRNA2), with respect to cells transfected 
with control siRNA (Figure 6C). Furthermore, the 
levels of secreted MMP-9 protein, measured by gelatin 
zymography after 48 h culture, were also reduced on c-jun 
siRNA transfected cells (Figure 6D). Altogether these 
results established that activation of p38 MAPK and c-jun 
were mainly responsible for the upregulation of MMP-9 
in response to ATO.
Figure 4: ATO upregulates MMP-9 in CLL cells via p38 MAPK activation. A, B. 3-5 x 106 MEC-1 cells in IMDM/0.1% FBS 
were incubated with or without 5 μM ATO for the indicated times and cell lysates analyzed by Western blotting. A representative experiment 
(A) and the quantitation of the three experiments performed (B), are shown. C. 3-5 x 106 MEC-1 cells in IMDM/0.1% FBS were incubated with 
or without SB203580 (SB, 10 μM), SP600125 (SP, 5 μM) or both. After 1 h at 37°C, 5 μM ATO was added or not and cells further incubated 
for 6 and 24 h. Total RNA was extracted and MMP9 mRNA levels analyzed by qPCR using TBP as internal control. Normalized average 
values are shown. FC, fold change. D. The conditioned medium of the same cells used in (C) was collected after 24 h and analyzed by gelatin 
zymography. The results from one representative experiment and the quantitation of the three experiments performed, after normalizing control 
values to 1, are shown. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, compared to their corresponding controls at each time point.
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Figure 5: The AP-1 transcription factor is responsible for the upregulation of MMP-9 by ATO. A. 3-5 x 106 MEC-1 cells 
in IMDM/0.1% FBS were incubated with or without 1 or 5 μM SR11302 (SR). After 1 h at 37°C, 5 μM ATO was added or not and cells 
further incubated for 6 and 24 h. MMP9 mRNA expression was analyzed by qPCR. B. The conditioned medium of MEC-1 cells, treated or 
not with the indicated inhibitors, was collected after 24 h, concentrated and analyzed by gelatin zymography. A representative experiment 
and the average quantitation of the three experiments performed are shown. C-E. MEC-1 cells were treated with ATO for the indicated 
times and JUN (C), FOS (D) and NFKB1 expression (E) was analyzed by qPCR, using TBP as internal control. F, G. Western blotting 
analyses of the indicated proteins upon treatment of MEC-1 cells with ATO for the indicated times. A representative experiment and the 
average quantitation of the three (F) or four (G) experiments performed is shown. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, compared to their 
corresponding controls at each time point.
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HMOX1 gene silencing upregulates p38 MAPK/
c-jun activation and increases MMP-9 expression
Previous studies in other cell systems have 
demonstrated a relation between HMOX1 and certain 
MMPs [30-32]. We therefore studied whether HMOX1 
regulated MMP-9 in CLL cells in response to ATO. To 
this end, we transfected MEC-1 cells with HMOX1 or 
control siRNAs and measured the expression of MMP-
9. The efficiency of the transfection was confirmed by 
Western blotting, which showed that gene silencing 
HMOX1 reduced the already low levels of this protein 
in control cells (Figure 7A). In cells treated with ATO 
there was a 5.9-fold (average of 4 experiments) HMOX1 
reduction after 24 h and a 5.2-fold reduction (average of 
4 experiments) after 48 h, compared to their respective 
control siRNA (Figure 7A).
Gelatin zymography analyses indicated that gene 
silencing HMOX1 significantly upregulated secreted 
MMP-9, both in the absence or presence of ATO (Figure 
7B), suggesting that HMOX1 negatively regulates MMP-
9. To determine if this regulation was at the transcriptional 
level, we measured by qPCR the expression of MMP9 
mRNA on cells transfected with control- or HMOX1 
siRNA. Figure 7C shows that MMP9 mRNA was 
significantly higher in HMOX1-silenced cells than in 
control siRNA-transfected cells. For control cells (no 
ATO), upregulation of MMP9 mRNA was clearly observed 
after 6 h. For cells treated with ATO, the maximal mRNA 
increase was also after 6 h, although significantly elevated 
MMP9 mRNA levels persisted after 24 h of treatment 
(Figure 7C). Altogether these results indicated that 
HMOX1 transcriptionally regulates MMP-9 expression in 
CLL cells.
To next study whether HMOX1 regulated MMP-
9 by influencing the p38 MAPK pathway we measured 
the activation of this kinase in MEC-1 cells transfected 
with control or HMOX1 siRNAs. The phosphorylation 
of JNK was also measured in these experiments as a 
control for the specificity of the effect. HMOX1 was 
hardly detectable after 2 h of treatment with 5 μM ATO, 
but the HMOX1 siRNA effectively reduced ATO-induced 
HMOX1 expression after 6 and 24 h of treatment (shown 
in Figure 7D for a representative experiment out of the 
three performed). p38 MAPK phosphorylation was very 
low or undetectable in control cells, but in the presence 
Figure 6: c-jun mediates the induction of MMP-9 by ATO. 15 x 106 MEC-1 cellswere nucleofected with two c-jun siRNAs (Jun1, 
Jun2) or a control siRNA (Ctl) for 16 h. JUN mRNA expression was analyzed by qPCR A. and phospho-c-jun expression by Western blot 
B. A representative analysis, as well as the quantitation of three experiments performed is shown. C. MEC-1 cells were nucleofected as in 
(A) and incubated with or without 5 μM ATO. MMP9 mRNA expression was analyzed by qPCR after 6 h with or without ATO treatment. 
Normalized average values are shown. D. The conditioned media of siRNA transfected-MEC-1 cells, incubated with or without ATO for 48 
h, was concentrated and analyzed by gelatin zymography, using actin as a loading control. A representative experiment is shown. Numbers 
indicate the normalized values of two different experiments. *P ≤ 0.05; ***,P ≤ 0.001.
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Figure 7: Gene silencing HMOX1 increases p38 MAPK/AP-1 activation and MMP-9 expression. A. 15 x 106 MEC-1 
cells were nucleofected with HMOX1 (H) or control (C) siRNAs and incubated with or without 5 μM ATO for 24 h or 48 h. HMOX1 
expression was analyzed by Western blotting. B. The conditioned media of the cells shown in (A) was concentrated and analyzed by gelatin 
zymography. A representative analysis, as well as the quantitation of the four experiments performed is shown. C. MEC-1 cells were 
nucleofected as in (A) and MMP9 mRNA expression analyzed by qPCR after 6 and 24 h of ATO treatment. Normalized average values are 
shown. D. 15 x 106 MEC-1 cells were nucleofected with HMOX1 (H) or control (C) siRNAs and treated with or without 5 μM ATO. At the 
indicated times, cells were lysed and analyzed by Western blotting. A representative experiment is shown. Numbers indicate the average 
values of three different experiments. Phosphorylated kinases were normalized with respect to their corresponding total protein; p-c-jun, 
c-jun, and c-fos were normalized with respect to vinculin. The conditioned media of these cells was analyzed by gelatin zymography, using 
actin as a loading control. *, #P ≤ 0.05; **, ##P ≤ 0.01; ***, ###P ≤ 0.001. *, control siRNA vs HMOX1 siRNA; #, control vs ATO.
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of ATO gene silencing HMOX1 increased p38 MAPK 
activation 1.8- and 1.35-fold, respectively, after 6 and 24 
h, compared to control siRNA (Figure 7D). In contrast, 
the phosphorylation of JNK was either unchanged or 
diminished by HMOX1 siRNA, after 2 or 6 h of ATO 
treatment, confirming the specificity towards p38 MAPK 
(Figure 7D).
Silencing HMOX1 also had a profound effect on 
the activation of c-jun, which increased 2.1-fold after 6 
h of ATO treatment, and remained significantly higher 
than the corresponding control after 24 h (Figure 7D). The 
total expression of c-jun in ATO-treated cells was also 
significantly enhanced by gene silencing HMOX1 at all 
times studied (Figure 7D). c-fos expression also showed 
a moderate, but not statistically significant, increase after 
2 h of ATO exposure in HMOX1-silenced cells, compared 
with control siRNA, with no further changes observed 
at longer times (Figure 7D). Parallel to the activation 
of p38 MAPK and c-jun, significant higher levels (1.8-
fold increase) of secreted MMP-9 were also observed by 
gelatin zymography in HMOX1-silenced cells after 24 h of 
ATO treatment (Figure 7D).
Overexpression of HMOX1 or modulation of its 
activity affects p38 MAPK/c-jun activation and 
MMP-9 expression
We next used the opposite strategy and 
overexpressed HMOX1 in MEC-1 cells using the 
CRISPR/dCas9 system. Western blotting analyses 
confirmed the expression of HMOX1 in cells transfected 
with the HMOX1 activation plasmid, even in the absence 
of ATO, confirming the functionality of the system 
(Figure 8A). Concomitant to HMOX1 overexpression, 
p38 MAPK phosphorylation decreased 1.7-fold in 
control cells and 3-fold in ATO-treated cells (Figure 8A). 
The phosphorylation and the total levels of c-jun also 
decreased (2.2-fold each) in HMOX1-transfected cells 
treated with ATO (Figure 8A). Downregulation of c-fos 
was also observed under these conditions (Figure 8A).
To further confirm the above results, we studied the 
effect of the HMOX1 inductor/activator CoPP and the 
HMOX1 inhibitor ZnPP on the activation of p38 MAPK 
and c-jun. After preliminary experiments, 3 μM CoPP 
and 2 μM ZnPP were chosen for the study. The activity 
of CoPP and ZnPP on HMOX1 was first confirmed by 
Western blotting analyses. As shown in Figure 8B for 
a representative experiment out of three performed, 
HMOX1 was undetectable in basal conditions but readily 
induced by both concentrations of ATO in control cells. In 
the absence of ATO, CoPP induced HMOX1 expression, 
confirming the activity of this compound. The combination 
of ATO and CoPP did not significantly increased HMOX1 
expression, likely reflecting that maximal induction had 
been already achieved (Figure 8B). ZnPP by itself did 
not induce HMOX1 expression (Figure 8B). However, 
when combined with ATO, ZnPP had a dual effect: 1) it 
potentiated the increase on HMOX1 expression induced 
by ATO, in agreement with the reported role of ZnPP as 
an inducer of HMOX1 and an inhibitor of its activity [33, 
34]; 2) it affected HMOX1 mobility in gels, suggesting 
that besides inhibiting HMOX1 activity, ZnPP binding 
induced a conformational change in HMOX1, further 
confirming the activity of this compound (Figure 8B).
CoPP did not significantly affect the induction 
of p38 MAPK phosphorylation by ATO, likely for the 
reasons mentioned above (Figure 8B). However, ZnPP 
significantly increased p38 MAPK phosphorylation by 
itself and both concentrations of ATO further enhanced this 
effect (Figure 8B), confirming the results obtained with 
the HMOX1 siRNA. In contrast, JNK phosphorylation 
decreased in cells treated with ZnPP in the presence of 
ATO, with respect to the corresponding controls (Figure 
8B). CoPP had no significant effect on c-jun expression, 
but ZnPP significantly increased (nearly 2-fold) c-jun, to 
similar levels with or without ATO (Figure 8B). These 
compounds did not change c-fos expression (Figure 8B). 
Parallel analyses by gelatin zymography indicated that 
CoPP was not able to significantly increase the amount 
of secreted MMP-9 and did not modify the levels induced 
by ATO (Figure 8B). However, ZnPP significantly 
increased the effect of ATO on MMP-9 production (Figure 
8B). Altogether these results established that HMOX1 
downregulates MMP-9 expression by interfering with 
activation of the p38 MAPK/c-jun signaling pathway.
HMOX1 enhances the apoptotic effect of ATO in 
CLL cells
Previous studies in several cell types have described 
an anti-apoptotic role for HMOX1 in response to ATO 
[35-37]. To determine whether HMOX1 influenced the 
apoptotic action of ATO in CLL cells, we first measured 
the viability of cells transfected with control or HMOX1 
siRNAs. No significant differences were observed 
between control and HMOX-1-silenced cells after 24 h 
(not shown). However, after 48 h of culture, the viability 
of cells transfected with HMOX1 siRNA was significantly 
higher than when transfected with control siRNA (values 
normalized to 100), both in the absence or presence of 
ATO (1.1- and 1.4-fold increase, respectively) (Figure 
9A). In agreement with these results, the viability of cells 
transfected with the HMOX1 activation plasmid was lower 
than in cells transfected with control plasmid, both in the 
absence, but particularly, in the presence of ATO (1.2- and 
1.6-fold decrease, respectively) (Figure 9B).
We also studied the effect of modulating HMOX1 
activity with CoPP or ZnPP, alone or combined with 
various concentrations of ATO, on cell viability. The 
viability of cells incubated in the absence of ATO was 
normalized to 100 in all cases. 3 μM CoPP alone did 
not decrease cell viability (98%, not shown), but when 
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combined with ATO enhanced the apoptotic effect of 
this agent at all concentrations tested (Supplementary 
Figure S2A). Indeed, combination index analyses using 
the CompuSyn software indicated that the interaction of 
CoPP and ATO was synergistic for all ATO concentrations, 
except for 8 μM, which was additive (Supplementary 
Figure S2A).
Similar analyses were carried out with the HMOX1 
inhibitor ZnPP. In this case, 2 μM ZnPP alone induced 
36% cell death (average of three experiments, not shown). 
When combined with ATO, the viability values obtained 
for 1 and 2 μM ATO were higher than 36%, indicating that 
ZnPP counteracted the apoptotic effect of ATO, as clearly 
observed at higher concentrations of ATO (Supplementary 
Figure S2B). Consistently, analyses of the combination 
index demonstrated an antagonistic interaction between 
ZnPP and ATO at all concentrations of ATO tested 
(Supplementary Figure S2B).
To confirm these results, we measured the viability 
of cells cultured in the absence or presence of 3 μM CoPP 
or 2 μM ZnPP and with or without 3 or 5 μM ATO, the 
concentrations used throughout our study. After 24 h culture 
in the absence of ATO the average (n=5) viability values 
were 75.3% (vehicle), 77% (+3 μM CoPP), and 64% (+2 
μM ZnPP), and were normalized to 100. The combination 
of CoPP with either 3 or 5 μM ATO significantly reduced 
cell viability, compared to control cells (Figure 9C). ZnPP 
had the opposite effect, inducing a moderate increase in cell 
viability when combined with 3 μM ATO but a significant 
increase upon combination with 5 μM ATO (Figure 9C).
To further establish the role of HMOX1 in the 
apoptosis of CLL cells induced by ATO we analyzed 
whether modulation of HMOX1 activity by CoPP and 
ZnPP affected the expression of Bcl-2 family proteins. As 
observed above for the regulation of p38 MAPK and c-jun 
(Figure 8B), CoPP did not significantly modify the levels 
Figure 8: Overexpressing HMOX1 or modulating its activity affects p38 MAPK/c-jun activation and MMP-9 
expression. A. 10 x 106 MEC-1 cells were nucleofected with CRISPR/dCas9 HMOX1 activation (pAct H) or control (pAct C) plasmids 
and incubated with or without 3 μM ATO. After 24 h, cell lysates were analyzed by Western blotting. Values represent the average of two 
different experiments. B. 3-5 x 106 MEC-1 cells were incubated for 1 h with or without 3 μM CoPP or 2 μM ZnPP. 5 μM ATO was added or 
not and cells further incubated for 24 h. Cell lysates and conditioned medium were analyzed by Western blotting and gelatin zymography, 
respectively. The results of one representative experiment and the normalized average values of the three experiments performed are shown. 
*P ≤ 0.05; **P ≤ 0.01.
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Figure 9: Pro-apoptotic role of HMOX1 in CLL cells in response to ATO. A. 10-15 x 106 MEC-1 cells were nucleofected with 
HMOX1 or control siRNAs and treated with or without 5 μM ATO for 48 h. Cell viability was analyzed by flow cytometry. B. 10 x 106 
MEC-1 cells were nucleofected with CRISPR/dCas9 HMOX1 or control plasmid and treated with or without 3 μM ATO for 24 h. Cell 
viability was determined as in (A). C. 3-5 x 106 MEC-1 cells were incubated with vehicle or the indicated compounds and treated with the 
indicated concentrations of ATO. After 24 h, cell viability was determined as explained in (A). D. MEC-1 cells, treated or not with CoPP or 
ZnPP, were incubated with the indicated concentrations of ATO for 24 h and analyzed by Western blotting. Numbers indicate the normalized 
average values (protein/vinculin) from the three cases analyzed. E. Average quantitation of the Bcl-xL/Bim and Bcl-xL/Bax ratios. *P ≤ 
0.05; **P ≤ 0.01; ***P ≤ 0.01. F. Schematic representation of the identified mechanisms of MMP-9 modulation by HMOX1 in CLL cells. 
ATO induces MMP-9 thought the activation of p38 MAPK/AP-1 pathway. ATO also induces the expression of HMOX1, which in turn 
transcriptionally downregulates MMP-9 by inhibiting p38 MAPK. G. Schematic drawing depicting how the levels of HMOX1 and MMP-9 
may determine the cell fate. Within a particular threshold, high levels of HMOX1 and low levels MMP-9 would favor apoptosis, while high 
levels of MMP-9 and lower levels of HMOX1 would support cell survival.
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of the anti-apoptotic protein Bcl-xL or the proapoptotic 
proteins Bim and Bax, with respect to controls (Figure 
9D). However, inhibition of HMOX1 function by ZnPP 
significantly increased Bcl-xL expression and decreased 
the levels of Bim and Bax (Figure 9D). Other proteins of 
this family (Bcl-2, Mcl-1 and Noxa) were not significantly 
modulated by ZnPP (not shown). Moreover, and because 
regulation of survival/apoptosis depends on the balance of 
anti-apoptotic versus pro-apoptotic Bcl-2 family proteins 
[38], we also measured the ratios Bcl-xL/Bim and Bcl-xL/
Bax. Figure 9E shows that both ratios were significantly 
upregulated upon cell treatment with ZnPP, both in the 
absence or presence of ATO.
In summary, our results establish that p38 MAPK/c-
jun signaling is responsible for the increase of MMP-9 
by ATO, and suggest a central role for HMOX1 in the 
modulation of this pathway and in the apoptotic response 
of CLL cells to ATO. A schematic drawing depicting these 
HMOX1 functions is shown in Figure 9F. An additional 
representation of how the levels of HMOX1 and MMP-9 
may determine cell fate (apoptosis vs survival) is shown 
in Figure 9G.
DISCUSSION
To expand our knowledge on the apoptotic 
mechanism induced by ATO and its potential use in CLL 
therapy, we have studied the global gene expression profile 
elicited by this agent in CLL cells. Our major findings 
are: 1) Gene expression analysis reflects an antioxidant 
and defensive cellular response to ATO; 2) ATO strongly 
upregulates HMOX1 and, to a lesser extent, MMP-9; 
3) The mechanism by which ATO upregulates MMP-
9 is via activation of the p38 MAPK/AP-1 pathway; 4) 
HMOX1 interferes with p38 MAPK/AP-1 activation and 
downregulates MMP-9; 5) HMOX1 exerts a pro-apoptotic 
role in CLL cells in response to ATO, synergistically 
enhancing the cytotoxicity of this agent.
Gene expression analyses by microarrays indicated 
that ATO regulated many genes in CLL cells. Importantly, 
this gene modulation was observed at clinically relevant 
concentrations of ATO [39, 40]. Most of the upregulated 
genes were allocated to the response to oxidative stress, 
endoplasmic reticulum stress (unfolded protein response), 
and organic/toxic substances, consistent with the induction 
of an antioxidant and defensive cell response. Accordingly, 
the most upregulated genes were HMOX1 and genes 
encoding several members of the metallothionein family 
(MT1F, MT1E, MT1G, and MT1X), with well-established 
antioxidant and detoxification functions, respectively [41, 
42]. Induction of HMOX1 in response to oxidative stress, 
elicited for example by arsenical-based compounds, has 
been reported in several cell systems [14, 17, 43, 44]. The 
role of HMOX1 in CLL is not well known and our present 
results are the first to show that ATO strongly upregulates 
HMOX1 (gene and protein) in CLL cells. These results 
are particularly relevant in view of recent studies 
demonstrating that, besides its antioxidant function, 
HMOX1 is involved in mitochondrial biogenesis in CLL 
and could represent a potential therapeutic target [23].
Another important molecule in CLL is MMP-9 
[11, 45-47] and our current analyses showed that MMP-9 
expression was also upregulated by ATO, both at the gene 
and protein level. These findings confirm our previous 
report showing that ATO increases membrane-associated 
MMP-9 in CLL cells [11]. The molecular mechanism 
underlying this effect was not previously studied, and 
we have addressed this in the present report. Our results 
clearly show that ATO upregulates MMP-9 via activation 
of the p38 MAPK. Although ATO also activated JNK 
in CLL cells, inhibition of this kinase did not decrease 
MMP-9 induction, ruling out its role in the upregulation 
of MMP-9 in these conditions. In other cell systems, p38 
MAPK mediates MMP-9 upregulation in response to 
several stimuli, including TNF-α and SDF-1/CXCR7 in 
bladder and ovarian, respectively, carcinoma cells [48, 
49], and clusterin/thrombospondin-1 in platelet-stimulated 
colon cancer [50]. In CLL cells, constitutive activation of 
p38 MAPK was required for MMP-9 production in CLL-
stromal cell co-cultures, as well as for the survival of 
CLL cells in this system [51]. Other authors have shown 
that p38 MAPK activity is associated to the induction of 
apoptosis in CLL cells [52, 53], indicating the dual role of 
this kinase in the survival of CLL cells.
Further analyses on the p38 MAPK signaling 
pathway demonstrated that AP-1 is the main transcription 
factor responsible for the induction of MMP-9 in response 
to ATO. This is consistent with the reported activation of 
AP-1 by p38 and other MAPK [54] and with the presence 
of several binding sites for AP-1 in the MMP-9 promoter 
[27, 28]. Indeed, the distal and proximal AP-1 binding 
sites have been shown to contribute to the transcriptional 
induction of MMP-9 in HT1080 cells, in response to 
various stimuli [55]. Although NF-κB is also known to 
induce MMP-9 transcription [27, 28], our results indicate 
that its contribution to the upregulation of MMP-9 by 
ATO, if any, is minimal, confirming our previous report 
showing that ATO inactivates NF-κB in primary CLL 
cells [10]. We have therefore identified the molecular 
mechanism by which ATO induces MMP-9 expression in 
CLL cells.
Previous reports in other cell systems have shown 
a connection between HMOX1 and the expression of 
several MMPs. For example, HMOX1 downregulated 
the expression and secretion of MMP-1 in chondrocytes 
[30] or plasma of patients with pulmonary tuberculosis 
[31]. Reduction of MMP-9 expression by HMOX1 was 
also observed in breast cancer cells [32]. We now show 
that HMOX1 transcriptionally downregulates MMP-9 
production in CLL cells by interfering with p38 MAPK/
AP-1 activation. The following evidences strongly support 
this conclusion: 1) gene silencing HMOX1 or inhibiting its 
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activity with ZnPP resulted in increased p38 MAPK/AP-1 
activation and MMP-9 production; 2) overexpression 
of HMOX1 or enhancement of its activity with CoPP 
decreased p38 MAPK activation. Additionally, these 
results are in agreement with a previous study showing 
that inhibition of HMOX1 in dendritic cells increases 
activation of the p38 MAPK signaling pathway [56]. 
The exact mechanism by which HMOX1 modulates p38 
MAPK in CLL cells is not known, but probably involves 
some of the metabolites derived from HMOX1 function. 
In support of this, it has been demonstrated that carbon 
monoxide, a by-product of heme catabolism by HMOX1, 
mediates anti-inflamatory effects by regulating p38 and 
other MAPKs [57]. Therefore, by-products of HMOX1 
can influence p38 MAPK activation and consequently, 
MMP-9 expression, as we observe. Based on our current 
results it is possible to speculate that the moderate increase 
in MMP-9 (2-fold), observed upon ATO treatment, could 
be due to the parallel repressive effect of HMOX1.
Besides regulating MMP-9 expression, our results 
show that HMOX1 enhances the cytotoxic effect of 
ATO in CLL cells in a synergistic manner, thus exerting 
a pro-apoptotic role in the response to this agent. 
Because we have previously shown that MMP-9 has an 
anti-apoptotic role in the presence of ATO (and other 
drugs) [11], downregulation of MMP-9 may be one of 
the mechanisms contributing to HMOX1 pro-apoptotic 
function. Our current findings differ from other studies 
showing a protective role for HMOX1 in other cellular 
systems [19-21, 58]. However, some evidences suggest 
that the protective properties of HMOX1 are restricted to 
a narrow threshold of expression and that HMOX1 may 
in fact have protective and cytotoxic functions, depending 
on the context [16, 22]. It has also been proposed that 
HMOX1 may display pro- and anti-oxidant properties 
[59], indirectly behaving as a pro- or anti-apoptotic 
protein. In this regard, and in agreement with our results, 
Hamamura et al. reported that induction of HMOX1 by 
cobalt protoporphyrin enhances the cytotoxic effect of 
bortezomib in T-cell leukemia cells [60]. Additionally, 
induction of HMOX1 via activation of the transcription 
factor Nrf2 by auranofin [24] or electrophilic compounds 
[61] increased the cytotoxic activity of these agents 
against CLL cells, confirming the apoptotic role of 
HMOX1.
In summary, our study is the first to report that 
HMOX1 negatively regulates MMP-9 expression in CLL 
cells in response to ATO, through modulation of the p38 
MAPK/AP-1 signaling pathway. Additionally, modulation 
of HMOX1 expression or activity has a direct impact in 
the cytotoxic potential of ATO. The role of oxidative stress 
in CLL is beginning to draw attention as a possible target 
in this disease [23, 24]. Our current report reinforces these 
studies and indicates that the combination of ATO with 
HMOX1 modulators may represent an efficient alternative 
for the clinical treatment of this malignancy.
MATERIALS AND METHODS
Patients, cells and cell cultures
Approval was obtained from the CSIC Bioethics 
Review Board for these studies. Peripheral blood samples 
from the 8 CLL patients listed in Table 1  were obtained 
after informed consent, and B-lymphocytes were purified 
as described [11]. The MEC-1 and EHEB cell lines, 
established from CLL patients [62] were purchased from 
the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany) and cultured 
in IMDM/10% FBS (MEC-1) or RPMI/10% FBS (EHEB).
Antibodies and reagents
Rabbit polyclonal antibodies (RpAbs) to JNK 
(sc-571) and c-fos (sc-52), and mouse monoclonal 
Abs (mAbs) to c-jun (sc-166540), IκB-α (sc-1643) 
and HMOX1 (sc-136961) were from Santa Cruz 
Biotechnology (Santa Cruz,  CA). mAbs to Vinculin 
(V9131) and β-actin (A5316) were from Sigma-Aldrich 
(St. Louis, MO). RpAbs to phospho-JNK (T183/y185), 
phospho-c-jun (S73), phospho-ERK1/2 (T202/Y204), 
phospho-p38 MAPK (T180/Y182) and p38 MAPK, and 
mAbs to ERK1/2 and phospho-IκB-α (S32/36) were from 
Cell Signaling Technology Inc. (Beverly, MA). Annexin 
V-FITC was from Immunostep (Salamanca, Spain). 
Propidium iodide (PI), MTT (3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazoliumbromide), arsenic trioxide (ATO), 
and the cobalt and zinc protoporphyrins [CoPP (HMOX1 
activator) and ZnPP (HMOX1 inhibitor)] were from 
Sigma-Aldrich. SR11302 (AP-1 inhibitor) was from Santa 
Cruz Biotechnology. MAPK inhibitors SB203580 (p38) 
and SP600125 (JNK) were from Calbiochem (Darmstadt, 
Germany).
Gene expression analysis by microarrays
5 x 106 MEC-1 cells were cultured in IMDM/0.1% 
FBS with or without 5 μM ATO for 24 hours. Total RNA 
was extracted and purified using the RNeasy® Mini 
kit (Qiagen, Limburg, Netherlands). Double-stranded 
cDNA and biotinylated cRNA were synthesized from 
200 ng total RNA using the Ambion® WT Expression 
Kit (Thermo Fisher Scientific, MA, USA). Biotin-
labeled cRNA was fragmented and hybridized to a 
GeneChip® Human Gene 1.0 ST Array (Affymetrix, 
Santa Clara, CA). Expression values were normalized 
and summarized using the Robust Multi-Array Average 
algorithm [63, 64]. Differential expression analyses in 
ATO-treated versus untreated samples were conducted 
by the Significance Analysis of Microarray method [65], 
setting the false discovery rate to 0.1 and considering a 
p value < 0.05 as statistically significant. Genes with 
significantly different expression (≥ 2-fold change) were 
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manually filtered and the resulting group functionally 
annotated using the BP_FAT category of Gene Ontology 
(GO) and the Database for Annotation, Visualization 
and Integrated Discovery (DAVID, National Institute 
of Allergy and Infectious Diseases) v6.7. GO BP_
FAT terms with an associated p value of ≤ 0.05 were 
considered significantly enriched. Clustering (non-
supervised hierarchical) and heat maps were conducted 
with TIGR Multiexperiment Viewer v4.9, from the TM4 
Software suite (Dana-Farber Cancer Institute, Boston, 
MA). The complete gene expression data sets have 
been deposited and are available online at the Gene 
Expression Omnibus repository (GEO ID: GSE78207).
Quantitative PCR
Total RNA isolation and cDNA amplification were 
performed as described [11]. Quantitative PCR (qPCR) 
was performed using iQTM SYBR® Green Supermix 
(Bio-Rad Laboratories, Hercules, CA), and the primers 
listed in Supplementary Table S3. All assays were 
performed in triplicate and the results were normalized 
according to the expression levels of TBP and expressed 
using the ΔΔCT method for quantization.
RNA interference experiments
The following siRNA sequences targeting 
human HMOX1 or c-jun were used: HMOX1: sense 
5′-CUGUGUCCCUCUCUCUGGA[dT][dT]-3′; siJun1: 
5′-GAUGGAAACGACCUUCUAU[dT][dT]-3′; siJun2: 
5′-CCUUCUAUGACGAUGCCCU[dT][dT]-3′. The siRNA 
sequence for negative control was: sense 5’-AUUGUA 
UGCGAUCGCAGACdTdT-3’. siRNA duplexes were 
verified to be specific for their targets by Blast search 
against the human genome and were custom-made by 
Sigma-Aldrich. 15 x 106 MEC-1 cells were nucleofected 
with 4 μM siRNAs using solution V and program T-02 
(Amaxa, Cologne, Germany), and assayed 16 h after 
transfection. Efficiency of the transfection was confirmed 
by qPCR and Western blotting.
Overexpression and regulation of HMOX1 
activity
The CRISPR/dCas9 system for HMOX1 expression 
(HMOX1 CRISPR Activation Plasmid) and the 
corresponding control were purchased from Santa Cruz 
Biotechnology. 10 x 106 MEC-1 cells were nucleofected 
with 5 μg plasmid system (Control or HMOX-1) as above, 
and assayed 16 h after transfection. Efficiency of the 
transfection was confirmed by Western blotting.
For regulation of HMOX1 activity, 1 x 106 MEC-1 
cells/ml in IMDM/0.1% FBS were incubated with 2 μM 
ZnPP, 3 μM CoPP or vehicle for 1 h at 37°C. ATO was 
added and cells further incubated for 24 h. The modulation 
of HMOX1 was confirmed by Western blotting.
Analysis of cell viability
Primary CLL cells in RPMI/0.1% FBS, MEC-1 
cells in IMDM/0.1% FBS, or EHEB cells in RPMI/0.1% 
FBS were incubated with ATO for 24-48 h and cell 
viability/apoptosis was determined on a Coulter Epics 
XL flow cytometer (Beckman Coulter, Fullerton, CA), 
using FITC-Annexin V and propidium iodide (PI). For 
MTT assays, 0.75 x 105 MEC-1 cells in IMDM/0.1% 
FBS were incubated with 50 μg MTT for 4 h in the dark. 
The blue MTT formazan precipitate was dissolved in 
isopropanol-HCl (24:1) and the absorbance at 540 nm was 
determined on a Multiskan Bichromatic microplate reader 
(Labsystems, Helsinki, Finland). Drug interaction analyses 
were performed using the CompuSyn software (BioSoft, 
Cambridge, UK), which allows the calculation of the 
combination index (CI) values based on the algorithm 
of Chou and Talalay [66]. Combination index values < 1 
Table 1: Clinical characteristics of CLL patients
#Patient Sex/Agea Stageb CD38/ZAP70c IgHv status
c
1 F/72 C/IV -/+ Mutated
2 M/70 B/II +/+ Unmutated
3 M/65 A/I -/- Mutated
4 M/79 B/II +/- Unmutated
5 M/59 C/IV +/+ Unmutated
6 F/73 A/II -/- Mutated
7 M/48 B/I +/+ Unmutated
8 F/54 A/0 +/- Unmutated
aM, male; F, female.
bClinical stage according to references [1, 2].
cThe coexpression of CD38 and ZAP-70, and IGHV gene mutational status have clinical prognostic value [1, 2].
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indicate synergism, values ≈ 1 (0.9-1.1) indicate additivity, 
and > 1, antagonism.
Other methods
Western blotting, gelatin zymography and statistical 
analyses were performed exactly as described [11]. All 
values are expressed as means ± standard deviation, except 
for qPCR analyses where means ± standard error is shown.
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